TrialAmerican journal of hematology2017

Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.

Pramod K Mistry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.